Renaissance Capital logo

Acrivon Therapeutics Priced, Nasdaq: ACRV

Phase 2 biotech developing proteomics-based precision oncology therapies.

Industry: Health Care

Latest Trade: $14.53 0.00 (0.0%)

First Day Return: +33.1%

Return from IPO: +16.2%

Industry: Health Care

We are a clinical stage biopharmaceutical company developing precision oncology medicines that we match to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing our proprietary proteomics-based patient responder identification platform. Recently approved targeted oncology treatments, such as kinase inhibitors, have transformed the cancer treatment landscape, and while the therapeutic benefit of these agents has provided significant benefit to patients, these targeted oncology treatments unfortunately only address the less than 10% of patients with cancers that harbor certain easily-identifiable genetic mutations. Our approach is designed to overcome the limitations of genomics-based patient selection methods. We do this by using our proprietary precision medicine platform, Acrivon Predictive Precision Proteomics, or AP3, to develop our pipeline of oncology drug candidates. Our AP3 platform enables the creation of drug-specific proprietary OncoSignature companion diagnostics that are used to identify the patients most likely to benefit from our drug candidates, which we refer to as patient responders. We are currently advancing our lead candidate, ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 with sub single-digit nM and single-digit nM potency, respectively, in a potentially registrational Phase 2 trial across multiple tumor types, which our AP3 platform predicts will have a high proportion of patient responders based on OncoSignature-predicted sensitivity to ACR-368.
more less
IPO News for Acrivon Therapeutics
more
IPO Data
IPO File Date 10/17/2022
Offer Price $12.50
Price Range $16.00 - $18.00
Offer Shares (mm) 7.6
Deal Size ($mm) $94
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 11/14/2022
Offer Price $12.50
Price Range $16.00 - $18.00
Offer Shares (mm) 7.6
Deal Size ($mm) $94
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
more
Company Data
Headquarters Watertown, MA
Founded 2016
Employees 42
Website www.acrivon.com